Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Ebola hemorrhagic fever — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for ebola hemorrhagic fever is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
potassium voltage-gated channel subfamily H member 2 (KCNH2) — KCNH2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 8IO4 · 3.5 Å · ligand none (apo structure). Experimental structure, not a prediction.
Ebola virus causes hemorrhagic fever with a high case-fatality rate, and treatment remains supportive. A 2014 review noted that a variety of specific treatments were still in the early stages of investigation. Subsequent reviews from 2015 and 2016 state plainly that no effective prophylaxis or treatment for filovirus diseases is yet commercially available. Human case fatality rates for Ebola virus disease can reach up to 90%.
During the 2014–2016 West Africa outbreak, several unapproved drugs were used to treat patients. This outbreak accelerated efforts to develop antiviral strategies, and some vaccine and drug candidates entered clinical trials. However, the 2015 and 2016 reviews both confirm that no effective prophylaxis or treatment is commercially available. The articles do not report any concrete survival or response rates from those clinical trials, nor do they name any specific drug that showed benefit.
What is still missing is the completion of properly controlled clinical trials that can demonstrate whether any candidate treatment reduces mortality. The evidence base lacks randomised data from adequately powered studies, and no drug has yet been approved for Ebola virus disease. Patient stratification by viral load, timing of treatment, and supportive care standards also remains unaddressed in the published summaries.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractEbola virus causes a hemorrhagic fever with a high case-fatality rate. Treatment remains supportive although a variety of specific treatments are still in the early stages of investigation. This report reviews the clinical virology of Ebola virus, the reported proposed treatments, and the current outbreak.
https://doi.org/10.3949/ccjm.81gr.14007AbstractFiloviruses (Ebola and Marburg viruses) cause severe hemorrhagic fever in humans and nonhuman primates. No effective prophylaxis or treatment for filovirus diseases is yet commercially available. The recent outbreak of Ebola virus disease in West Africa has accelerated efforts to develop anti-Ebola virus prophylaxis and treatment, and unapproved drugs were indeed used for the treatment of patients during the outbreak. This article reviews previous researches and the latest topics on vaccine and therapy for Ebola virus disease.
https://doi.org/10.2222/jsv.65.61AbstractEbolaviruses, members of the family Filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates, with human case fatality rates of up to 90%. No effective prophylaxis or treatment for Ebola virus disease (EVD) is yet commercially available. During the latest outbreak of EVD in West Africa, several unapproved drugs were used for the treatment of patients. This outbreak has indeed accelerated efforts to develop antiviral strategies and some of the vaccine and drug candidates have undergone clinical trials. This article reviews previous researches and recent advances on the development of vaccine, therapeutics, and diagnostics for EVD.
https://doi.org/10.2222/jsv.66.63Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
